TB-500 (Thymosin Beta-4): Actin-Regulating Peptide for Injury Recovery and Repair
This article is informational in nature. TB-500 is not approved for human clinical administration in the United States or the European Union.
1. Molecular Profile and Structural Comparison with Tβ4
TB-500 is a synthetic, truncated peptide analog of thymosin beta-4 (Tβ4), a 43-amino acid, 5 kDa acidic polypeptide that acts as the primary G-actin sequestering molecule in mammalian cells. Tβ4 features a central actin-binding domain flanked by terminal helices, with the C-terminal AGES domain mediating cardioprotective signaling.
Synthetic TB-500 (Ac-LKKTETQ-OH) corresponds strictly to residues 17 through 23 of Tβ4, containing the Wiscott-Aldrich syndrome protein (WASp) homology domain 2 (WH2) actin-binding motif. It lacks the nuclear localization signal and the cardioprotective AGES domain, focusing its activity on actin regulation, angiogenesis, and cell migration in the musculoskeletal system to support Repair & Recovery.
2. Actin Regulation and Cellular Motility
TB-500's primary mechanism of action is the regulation of intracellular actin dynamics, balancing monomeric G-actin and polymeric F-actin. Cell migration for wound healing requires rapid actin polymerization at the leading edge to form lamellipodia and filopodia.
The LKKTET sequence of TB-500 binds subdomain 3 of the G-actin monomer, capping both ends to prevent premature F-actin assembly. Chemotactic signaling triggers dissociation, allowing the WH2 motif to act as a "leaky" cap for rapid G-actin exchange with profilin. This drives explosive actin polymerization at the injury site, accelerating wound closure. Engineered tandem Tβ4 (tTB4) variants show even faster corneal repair kinetics.
3. Angiogenic Properties and Endothelial Progenitor Cell Recruitment
Capillary network formation is essential to heal ischemic necrosis. TB-500 stimulates VEGF secretion by activating receptor tyrosine kinases. It initiates the PI3K cascade, recruiting Akt to the membrane.
Phosphorylated Akt activates endothelial nitric oxide synthase (eNOS), producing nitric oxide (NO) to induce vasodilation and vascular permeability, allowing endothelial cells to migrate. Simultaneously, TB-500 upregulates CXCR4 expression on bone marrow-derived endothelial progenitor cells (EPCs), enhancing their recruitment and homing via the SDF-1alpha axis to damaged muscle beds.
4. Anti-Inflammatory Signaling
Tissue trauma triggers inflammatory cytokines. TB-500 suppresses the NF-κB transcription complex. In typical pathology, pattern recognition receptors activate the IKK complex, leading to IκB degradation and NF-κB p50/p65 nuclear translocation to transcribe TNF-alpha, IL-1beta, and IL-6.
TB-500 suppresses phosphorylation of the NF-κB p65 subunit at Ser279, keeping it inactive in the cytoplasm. It also attenuates the NLRP3 inflammasome in macrophages, downregulating JNK/p38 MAPK expression and reducing ROS, thereby preventing caspase-1 activation and the maturation of IL-18 to mitigate joint inflammation.
5. Anti-Fibrotic Mechanisms: Tβ4-POP-Ac-SDKP Axis and TGF-β
Excessive extracellular matrix deposition by myofibroblasts results in restrictive fibrosis. TB-500 regulates collagen synthesis by inhibiting the Transforming Growth Factor-beta (TGF-β) network. POP (prolyl oligopeptidase) cleaves the N-terminus of Tβ4 to produce the anti-fibrotic tetrapeptide Ac-SDKP (N-acetyl-seryl-aspartyl-lysyl-proline).
Ac-SDKP blocks the transition of fibroblasts into alpha-SMA-expressing myofibroblasts by downregulating TGF-β1 and Smad2/3 phosphorylation, which prevents the Smad4 co-complex from transcribing fibrotic genes. In bleomycin-induced pulmonary fibrosis models, this axis reduces hydroxyproline levels, collagen-I, and collagen-III, ensuring organized connective tissue over hypertrophic scar tissue.
6. Clinical Tissue Repair
Topical Tβ4 hydrogel (RGN-137) upregulates laminin-5 to accelerate wound closure. Phase II clinical trials of 0.03% RGN-137 demonstrated accelerated venous stasis and pressure ulcer healing, reducing healing times by a month compared to placebos, leading to Phase III trials for Epidermolysis Bullosa.
For musculoskeletal trauma, mesenchymal stem cells seeded on PLGA scaffolds loaded with Tβ4 exhibit accelerated tenogenesis. In muscle injury, it recruits satellite cells for myoblast fusion into multinucleated myotubes, while the Ac-SDKP axis prevents fibrotic adhesions. In growth plates, it acts on stem cells to drive chondrocyte expansion, upregulating pro-MMP 9 for bone mineralization and accelerating trabecular bone calluses formation.
7. Pharmacokinetics, ADME, and Anti-Doping Equine Models
Phase I trials of IV RGN-352 show linear, dose-proportional PK curves, with half-lives extending from 0.95 hours (42 mg) to 2.1 hours (1260 mg). Subcutaneous injection of TB-500 yields rapid absorption with a Cmax of 200-400 ng/mL within 0.5 to 1.0 hour (6 mg/kg dose).
Subcutaneous bioavailability ranges from 60% to 80%. The peptide accumulates at hypoxic injury sites, degrades via serum peptidases, and clears renally. In equine sports, where TB-500 is monitored to prevent doping, LC-MS methods detect the peptide down to 0.02 ng/mL in plasma and 0.01 ng/mL in urine, confirming its rapid clearance profile.
8. Synergistic Healing Stacks and Safety Profile
Regenerative medicine stacks TB-500 with BPC-157 and GHK-Cu (the "Wolverine Stack"). BPC-157 activates FAK and upregulates EGR-1 for localized vessel sprouting, while TB-500 provides the necessary cell motility. GHK-Cu regulates MMP/TIMP for collagen remodeling and cross-linking to provide tensile strength, while TB-500's POP-mediated Ac-SDKP restricts fibrosis.
WADA bans all Tβ4 derivatives under Section S2. Gray-market synthesis carries contamination risks. Angiogenesis upregulation raises concerns regarding neovascularization in solid tumors, and high doses may affect coagulation, though RegeneRx's full-length pipeline (RGN-137, RGN-259, RGN-352) has shown exceptional tolerability.